Korea To Bolster Fast-Track System With Speedier Drug Approvals In Mind
This article was originally published in SRA
Executive Summary
South Korea plans to draw up detailed guidelines for a fast-track drug review and approval system this year to increase applications for such reviews, provide the pharma industry with a clearer understanding of the process, and provide timely patient access to more treatment options.
You may also be interested in...
Korea To Introduce Fast-Track Review For Cutting-Edge Biologics, Devices
South Korea is set to adopt fast-track review systems for cutting-edge biologics and medical devices late this year as it continues to nurture the biotech industry and in line with global trends
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.